These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24129137)

  • 41. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
    Kiltz U; Heldmann F; Baraliakos X; Braun J
    Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
    J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis.
    Burgos-Vargas R; Rojas-Serrano J
    J Rheumatol; 2005 Sep; 32(9):1637-40. PubMed ID: 16142852
    [No Abstract]   [Full Text] [Related]  

  • 44. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Golimumab for treatment of axial spondyloarthritis.
    Rios Rodriguez V; Poddubnyy D
    Immunotherapy; 2016 Feb; 8(2):107-15. PubMed ID: 26798943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
    J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Golimumab for the treatment of axial spondyloarthritis.
    Gelfer G; Perry L; Deodhar A
    Expert Rev Clin Immunol; 2016; 12(1):9-18. PubMed ID: 26523483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biologics in spondyloarthritis: TNFα inhibitors and other agents.
    Toussirot É
    Immunotherapy; 2015; 7(6):669-81. PubMed ID: 26058432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability.
    Bandinelli F; Scazzariello F; Pimenta da Fonseca E; Barreto Santiago M; Marcassa C; Nacci F; Matucci Cerinic M
    Drug Des Devel Ther; 2016; 10():3717-3724. PubMed ID: 27881910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort.
    Bedaiwi M; Sari I; Thavaneswaran A; Ayearst R; Haroon N; Inman RD
    J Rheumatol; 2015 Dec; 42(12):2354-60. PubMed ID: 26523020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The BeSt way of withdrawing biologic agents.
    Allaart CF; Lems WF; Huizinga TW
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S14-8. PubMed ID: 24129130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience.
    Can M; Aydın SZ; Niğdelioğlu A; Atagündüz P; Direskeneli H
    Int J Rheum Dis; 2012 Dec; 15(6):526-30. PubMed ID: 23253235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial.
    Weiss PF; Sears CE; Brandon TG; Forrest CB; Neu E; Kohlheim M; Leal J; Xiao R; Lovell D
    Trials; 2023 Feb; 24(1):100. PubMed ID: 36755328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Axial spondyloarthritis and ankylosing spondylitis].
    Nordström D; Kauppi M
    Duodecim; 2010; 126(12):1467-74. PubMed ID: 20617750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Certolizumab pegol in axial spondyloarthritis.
    Song IH; Rudwaleit M
    Expert Rev Clin Immunol; 2013 Dec; 9(12):1161-72. PubMed ID: 24215406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.